Duos Technologies Reports 112% Increase in Quarterly Revenue
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 12 2025
0mins
Get Free Real-Time Notifications for Any Stock
Monitor tickers like DUOT with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
Analyst Views on DUOT
Wall Street analysts forecast DUOT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DUOT is 14.00 USD with a low forecast of 14.00 USD and a high forecast of 14.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 10.830
Low
14.00
Averages
14.00
High
14.00
Current: 10.830
Low
14.00
Averages
14.00
High
14.00
About DUOT
Duos Technologies Group, Inc., develops and deploys technology systems with a focus on inspecting and evaluating moving vehicles. The Company operates under its brand name duostech. Its technology focus is within the Vision Technology market sector and, more specifically, the Machine Vision subsector. Machine Vision companies provide imaging-based automatic inspection and analysis for process control for industry with potential expansion into other markets. The Company’s flagship product, the Railcar Inspection Portal (RIP), enables freight and transit railroad customers and selects government agencies to conduct fully automated railcar inspections in real-time as trains move at full speed. It has also developed the Automated Logistics Information System (ALIS) which can automate gatehouse operations where transport trucks enter and exit large logistics and intermodal facilities. Its subsidiaries include Duos Technologies, Inc., Duos Edge AI, Inc., and Duos Energy Corporation.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Duos Technologies (DUOT) Expands AI Platform, Shares Surge 13.03%
- Stock Surge: Duos Technologies shares rose 13.03% to $11.49, reflecting strong market confidence in the expansion of its Duos EDGE AI platform, which is expected to enhance the company's market position in safety and automation.
- Market Expansion: The company announced the rollout of its AI-driven safety and automation solutions in Texas and new markets, which is anticipated to drive increased adoption among existing clients and create opportunities with new customer segments and geographies, enhancing future growth potential.
- Active Trading: On the day of the announcement, DUOT's trading volume was significantly above its average daily level, indicating strong investor interest in the company's expansion plans, further propelling the stock price upward.
- Price Volatility: DUOT opened at $10.50, reached an intraday high of $11.60, and a low of $10.48, reflecting optimistic market expectations for its future performance, with a 52-week price range of $4.50 - $12.10, indicating considerable price volatility.
Continue Reading
Ascendiant Raises Duos Technologies Price Target to $14
- Price Target Increase: Ascendiant Capital raised the price target for Duos Technologies Group, Inc. from $11.5 to $14, with analyst Edward Woo maintaining a Buy rating, indicating confidence in the company's future growth potential.
- Market Performance: Duos Technologies shares closed at $10.17 on Monday, suggesting that despite the price target increase, the market remains cautious about its potential, as the current price is still below the new target.
- Maison Solutions Target Adjustment: Ascendiant Capital also raised the price target for Maison Solutions Inc. from $4.25 to $4.5 while maintaining a Buy rating, reflecting optimism about its business outlook.
- Mereo BioPharma Downgrade: Jefferies cut the price target for Mereo BioPharma Group plc from $7 to $0.5 and downgraded the stock from Buy to Hold, indicating concerns about its future performance.
Continue Reading